NCT00736047View on ClinicalTrials.gov

Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Smokers
Interventions
BIOLOGICAL

NIC002

BIOLOGICAL

Placebo

Trial Locations (2)

Unknown

Novartis Investigative Site, Mainz

Novartis Investigator Site, Neuss

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00736047 - Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking. | Biotech Hunter | Biotech Hunter